Drug Pricing
Commentary
Facts, Economic Reason No Match for Left’s Drug Pricing Fixation
Last week, the U.S. Senate Finance Committee held a hearing, “Prescription Drug Price Inflation: An Urgent Need to Lower Drug Prices in Medicare.” It’s rare to see so many falsehoods in so few words. The idea that drug-price inflation is especially bad or that it poses some sort of threat to
Commentary
Drug Pricing Reforms Should Expand Choice, Not Government Control
As President Biden‘s recent State of the Union address made clear, drug pricing will remain a top policy issue for the foreseeable future. The president is correct that something must be done, but his proposals are wrongheaded and will only make things worse. Instead of focusing on government price controls, Congress
Blog
Biden’s Non-Plan for Fighting Inflation
In a recent survey, Americans ranked inflation as the most urgent issue facing the country. So, our ears perked up when Pres. Biden began laying out his plan to bring down inflation in his State of the Union address. After listening to his speech, you can’t help but think that
Commentary
Light starts to shine on opaque drug pricing tactics
Late last month, the Federal Trade Commission announced it would seek public comments on the ways pharmacy benefit managers distort the prices of prescription drugs. PBMs deserve the scrutiny, as they’re to blame for much of the rise in prescription drug costs. Insurers hire PBMs to negotiate drug prices with
Commentary
High Healthcare Spending Doesn’t Bolster Case for Single-Payer
Does the United States spend too much on healthcare? A look at the lower levels of healthcare spending in peer countries like Canada and the United Kingdom would seem to indicate as much. But a closer look at those numbers reveals a far more complex story. Take the matter of
Drug Pricing
Wayne Winegarden Discusses Prescription Drug Prices on Scripps National News
Watch PRI’s Wayne Winegarden, director of our Center for Medical Economics and Innovation, discuss efforts by the Federal Trade Commission to considering ordering large pharmacy benefits managers to study the competitive impact of contractual provisions, reimbursement adjustments, and other practices affecting drug prices on Scripps National News.
Commentary
The FDA Needs Reform – Biden’s Nominee Is Not the Person to Do It
When President Joe Biden nominated former Obama-era Food and Drug Administration Commissioner Dr. Robert Califf to return to his old post, he made what was widely seen as a safe, if uninspired, choice. He easily sailed through a Dec. 14 Senate committee hearing to vet him. “[Califf] gushed about his love of high-quality
Drug Prices
NEW STUDY: Creating Two-Part Drug Pricing System Would Ensure Prices More Accurately Reflect How Patients
Establishing a two-part drug pricing system quantifying separate values for a drug’s innovation and production would create an efficient market and a more accurate reflection of how patients value a drug compared to those produced by centralized organizations, argues a new report released today by the Center for Medical Economics
Commentary
Build Back Better’s Drug Reforms Make American Health Care Worse
Last week, President Joe Biden emphasized the importance of the drug pricing proposals in the Democrats’ roughly $2 trillion Build Back Better spending package. “I think it’s safe to say that all of us, all of us, whatever our age, wherever we live, we can agree that prescription drugs are outrageously expensive
Commentary
Comprehensive Regulatory Reform From The Bottom Up: The Case Of 340B
Using the ruse of “price negotiation”, the proponents of the Build Back Better legislation are pushing an ill-fated drug price control plan. Patients will bear exceptionally large costs should their idea of government-directed prices become law. These costs will include lower health outcomes due to reduced access to innovative drugs.
Facts, Economic Reason No Match for Left’s Drug Pricing Fixation
Last week, the U.S. Senate Finance Committee held a hearing, “Prescription Drug Price Inflation: An Urgent Need to Lower Drug Prices in Medicare.” It’s rare to see so many falsehoods in so few words. The idea that drug-price inflation is especially bad or that it poses some sort of threat to
Drug Pricing Reforms Should Expand Choice, Not Government Control
As President Biden‘s recent State of the Union address made clear, drug pricing will remain a top policy issue for the foreseeable future. The president is correct that something must be done, but his proposals are wrongheaded and will only make things worse. Instead of focusing on government price controls, Congress
Biden’s Non-Plan for Fighting Inflation
In a recent survey, Americans ranked inflation as the most urgent issue facing the country. So, our ears perked up when Pres. Biden began laying out his plan to bring down inflation in his State of the Union address. After listening to his speech, you can’t help but think that
Light starts to shine on opaque drug pricing tactics
Late last month, the Federal Trade Commission announced it would seek public comments on the ways pharmacy benefit managers distort the prices of prescription drugs. PBMs deserve the scrutiny, as they’re to blame for much of the rise in prescription drug costs. Insurers hire PBMs to negotiate drug prices with
High Healthcare Spending Doesn’t Bolster Case for Single-Payer
Does the United States spend too much on healthcare? A look at the lower levels of healthcare spending in peer countries like Canada and the United Kingdom would seem to indicate as much. But a closer look at those numbers reveals a far more complex story. Take the matter of
Wayne Winegarden Discusses Prescription Drug Prices on Scripps National News
Watch PRI’s Wayne Winegarden, director of our Center for Medical Economics and Innovation, discuss efforts by the Federal Trade Commission to considering ordering large pharmacy benefits managers to study the competitive impact of contractual provisions, reimbursement adjustments, and other practices affecting drug prices on Scripps National News.
The FDA Needs Reform – Biden’s Nominee Is Not the Person to Do It
When President Joe Biden nominated former Obama-era Food and Drug Administration Commissioner Dr. Robert Califf to return to his old post, he made what was widely seen as a safe, if uninspired, choice. He easily sailed through a Dec. 14 Senate committee hearing to vet him. “[Califf] gushed about his love of high-quality
NEW STUDY: Creating Two-Part Drug Pricing System Would Ensure Prices More Accurately Reflect How Patients
Establishing a two-part drug pricing system quantifying separate values for a drug’s innovation and production would create an efficient market and a more accurate reflection of how patients value a drug compared to those produced by centralized organizations, argues a new report released today by the Center for Medical Economics
Build Back Better’s Drug Reforms Make American Health Care Worse
Last week, President Joe Biden emphasized the importance of the drug pricing proposals in the Democrats’ roughly $2 trillion Build Back Better spending package. “I think it’s safe to say that all of us, all of us, whatever our age, wherever we live, we can agree that prescription drugs are outrageously expensive
Comprehensive Regulatory Reform From The Bottom Up: The Case Of 340B
Using the ruse of “price negotiation”, the proponents of the Build Back Better legislation are pushing an ill-fated drug price control plan. Patients will bear exceptionally large costs should their idea of government-directed prices become law. These costs will include lower health outcomes due to reduced access to innovative drugs.
